ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy 
Blockpass and RWA Inc. Partner to Effect Verifiable Trust in Real World Asset & DePIN Tokenization Saul Mishkin is the Featured Subject of a New Interview
The serial entrepreneur and president and CEO of NEX-XOS Worldwide sat down to discuss the…
Precision Home Pros Highlights Its Founder’s Uplifting Biography
The Texas-based all-purpose smart home and security firm calls attention to the unique and inspirational…
Jadestone Energy PLC Announces Dividend Declaration
SINGAPORE, SINGAPORE / ACCESSWIRE / June 11, 2021 / Jadestone Energy plc (the ‘Company‘ or…
Digital Realty Announces Availability of AWS Direct Connect 100G Dedicated Connections on PlatformDIGITAL® in Seattle and Dublin
Low-latency, high-availability connections at key centers of data exchange power new possibilities of scale for…
Orphazyme addresses recent trading activity
Orphazyme A/SCompany announcement        No. 15/2021Company Registration No. 32266355 Copenhagen – June 11, 2021 – Orphazyme A/S…
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies…
Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress
Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual…
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia Â
     New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational…
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults…
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naĂŻve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when…
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises…
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
– Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in…
X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021
Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus…
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies…
Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0%…
New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA)
Data from JEWELFISH, the first trial in a diverse population aged 1 to 60 years…
Greenrose Acquisition Corp Announces Intention to Voluntarily Delist from Nasdaq and List on the OTCQX Best Market
Listing Transition to Proceed as Previously Announced to Maintain Regulatory Compliance as a U.S.-Based, Plant-Touching…
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
 Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting…
NextCure to Present at the JMP Securities Life Sciences Conference
BELTSVILLE, Md., June 10, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical…
Biogen Announces Investor Day on September 21, 2021
CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced today that…